Puja P Khanna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2521172/publications.pdf

Version: 2024-02-01

27 papers 3,693 citations

394421 19 h-index 26 g-index

27 all docs

27 docs citations

times ranked

27

3765 citing authors

#	Article	IF	CITATIONS
1	Remission in Gout: Concepts From a Patient Perspective. Journal of Rheumatology, 2022, , jrheum.211285.	2.0	O
2	Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. Arthritis and Rheumatology, 2021, 73, 1523-1532.	5.6	30
3	Performance of Anti–Topoisomerase I Antibody Testing by Multiple-Bead, Enzyme-Linked Immunosorbent Assay and Immunodiffusion in a University Setting. Journal of Clinical Rheumatology, 2020, 26, 115-118.	0.9	18
4	Development and Pilot Testing of MyGoutCare. Journal of Clinical Rheumatology, 2020, 26, 320-326.	0.9	3
5	Systemic Urate Deposition: An Unrecognized Complication of Gout?. Journal of Clinical Medicine, 2020, 9, 3204.	2.4	36
6	2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care and Research, 2020, 72, 744-760.	3.4	420
7	Evaluation of Proposed Criteria for Remission and Evidenceâ€Based Development of Criteria for Complete Response in Patients With Chronic Refractory Gout. ACR Open Rheumatology, 2019, 1, 236-243.	2.1	7
8	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Annals of the Rheumatic Diseases, 2019, 78, 1592-1600.	0.9	72
9	Gout. Nature Reviews Disease Primers, 2019, 5, 69.	30.5	326
10	Gout: a patrician malady no more. Lancet Diabetes and Endocrinology, the, 2018, 6, 263-264.		9
	Godd, a patrician manady no more, cancer blaseces and chaselinology, the, 2016, 6, 203 20 1.	11.4	2
11	Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases. Quality of Life Research, 2018, 27, 755-764.	3.1	52
11	Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases. Quality		
	Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases. Quality of Life Research, 2018, 27, 755-764. Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. Digestive Diseases and Sciences,	3.1	52
12	Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases. Quality of Life Research, 2018, 27, 755-764. Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. Digestive Diseases and Sciences, 2017, 62, 1186-1192. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).	2.3	52 36
12	Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases. Quality of Life Research, 2018, 27, 755-764. Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. Digestive Diseases and Sciences, 2017, 62, 1186-1192. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases, 2017, 76, 811-820. Racial differences in health-related quality of life and functional ability in patients with gout.	3.1 2.3 0.9	52 36 141
12 13	Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases. Quality of Life Research, 2018, 27, 755-764. Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. Digestive Diseases and Sciences, 2017, 62, 1186-1192. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases, 2017, 76, 811-820. Racial differences in health-related quality of life and functional ability in patients with gout. Rheumatology, 2017, 56, 103-112.	3.1 2.3 0.9	52 36 141 14
12 13 14	Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases. Quality of Life Research, 2018, 27, 755-764. Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. Digestive Diseases and Sciences, 2017, 62, 1186-1192. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases, 2017, 76, 811-820. Racial differences in health-related quality of life and functional ability in patients with gout. Rheumatology, 2017, 56, 103-112. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift. Postgraduate Medicine, 2016, 128, 34-40. Performance of Gout Impact Scale in a longitudinal observational study of patients with gout.	3.1 2.3 0.9 1.9	52 36 141 14 25

#	Article	IF	CITATIONS
19	Evolution of management of gout. Current Opinion in Rheumatology, 2015, 27, 139-146.	4.3	26
20	Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Gastrointestinal Symptom Scales. American Journal of Gastroenterology, 2014, 109, 1804-1814.	0.4	190
21	Treatment of acute gout: A systematic review. Seminars in Arthritis and Rheumatism, 2014, 44, 31-38.	3.4	73
22	Development of an Online Library of Patient-Reported Outcome Measures in Gastroenterology: The GI-PRO Database. American Journal of Gastroenterology, 2014, 109, 234-248.	0.4	25
23	Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health and Quality of Life Outcomes, 2012, 10, 117.	2.4	152
24	2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care and Research, 2012, 64, 1447-1461.	3.4	598
25	2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care and Research, 2012, 64, 1431-1446.	3.4	1,268
26	Patient-reported Outcomes in Chronic Gout: A Report from OMERACT 10. Journal of Rheumatology, 2011, 38, 1452-1457.	2.0	84
27	Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. Rheumatology, 2010, 49, 955-959.	1.9	47